Login to Your Account



Clinic Roundup


Tuesday, April 5, 2011
Stealth Peptides Inc., of Boston, reported results of a Phase I study in healthy volunteers of Bendavia, a compound that targets the mitochondrion to treat ischemia reperfusion injury. Volunteers received a single dose of Bendavia administered as an intravenous infusion over an extended period. Bendavia appears to be safe and well tolerated at the dose evaluated, with no serious adverse events reported.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription